Japan Pharma Archives | Report Store

show blocks helper

Sort by Default Order
- Default Order
- Name
- Price
- Date
- Popularity

Click to order products descending

Display 15 Products per page

Astellas Company Analysis

$3,000.00

Analysis of Astellas’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
September 19, 2018
Find out more
Shire Company Analysis

$3,000.00

PharmaVitae explores Shire’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts
August 30, 2018
Find out more
Japan Pharma Outlook 2027

$3,000.00

PharmaVitae explores and visualizes market dynamics in the Japan Pharma peer set out to 2027* through analysis and in-house sales forecasts for more than 320 products.
July 2, 2018
Find out more
Mitsubishi Tanabe Company Analysis

$3,000.00

Updated analysis and forecasts based on Q1 2017 company-reported sales.
October 6, 2017
Find out more
Takeda

$3,000.00

Analysis of Takeda’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2014–24.
September 19, 2017
Find out more
Dainippon Sumitomo Company Analysis

$3,000.00

Analysis of Dainippon Sumitomo’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
September 19, 2017
Find out more
Shionogi Company Analysis

$3,000.00

Updated analysis and forecasts based on 2016 company-reported sales.

Pharmavitae Analytics explores Shionogi’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
August 31, 2017
Find out more
Otsuka Company Analysis

$3,000.00

PharmaVitae explores Otsuka’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
August 28, 2017
Find out more
Eisai Company Analysis

$3,000.00

Pharmavitae Analytics explores Eisai’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
August 28, 2017
Find out more
Daiichi Sankyo Company Analysis

$3,000.00

PharmaVitae explores Daiichi Sankyo’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
August 22, 2017
Find out more
Shinogi

$3,000.00

Analysis of Shionogi’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
September 28, 2016
Find out more
Japan Pharma Outlook

$3,000.00

Datamonitor’s Japan Pharma peer set contains the top 10 companies headquartered in Japan: Takeda Pharmaceuticals, Astellas Pharma, Daiichi Sankyo, Otsuka Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Dainippon Sumitomo, Shionogi & Co and Kyowa Hakko Kirin.
September 28, 2016
Find out more

Japan Pharma

Japan Pharma

Astellas Company Analysis

Shire Company Analysis

Japan Pharma Outlook 2027

Mitsubishi Tanabe Company Analysis

Takeda

Dainippon Sumitomo Company Analysis

Shionogi Company Analysis

Otsuka Company Analysis

Eisai Company Analysis

Daiichi Sankyo Company Analysis

Shinogi

Japan Pharma Outlook